METASTATIC LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA
Clinical trials for METASTATIC LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise in Tough-to-Treat lung cancer
Disease control OngoingThis study tests two experimental treatments—cabozantinib alone or combined with nivolumab—against standard chemotherapy for people with advanced non-squamous non-small cell lung cancer that has come back. About 117 adults with stage IV disease are taking part. The goal is to see…
Matched conditions: METASTATIC LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:44 UTC
-
New combo aims to halt lung cancer growth
Disease control OngoingThis study tests a new drug combination for people with advanced EGFR-mutant non-small cell lung cancer. The two drugs, LY3295668 and osimertinib, work by blocking enzymes that help cancer cells grow. The goal is to find the best dose and see if the combination can control the di…
Matched conditions: METASTATIC LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:18 UTC
-
New combo aims to shrink lung tumors when immunotherapy fails
Disease control OngoingThis study tests a new drug, pevonedistat, combined with standard chemotherapy (carboplatin and paclitaxel) in people with advanced non-small cell lung cancer that has already been treated with immunotherapy. The goal is to see if this combination can shrink tumors or stop them f…
Matched conditions: METASTATIC LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:17 UTC